A lowered LCBI after PCSK9 inhibitor treatment means plaques are less likely to rupture, decreasing the risk of major adverse cardiovascular events (MACE) like myocardial infarction, stroke, and death [99]. This evidence concerns the gene PCSK9 and stroke disorder.